Bioqual Inc (BIOQ)
72.50
0.00 (0.00%)
USD |
OTCM |
May 02, 16:00
Bioqual Enterprise Value: 58.41M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 58.41M |
| May 01, 2024 | 58.41M |
| April 30, 2024 | 58.41M |
| April 29, 2024 | 60.64M |
| April 26, 2024 | 60.64M |
| April 25, 2024 | 60.64M |
| April 24, 2024 | 60.64M |
| April 23, 2024 | 60.64M |
| April 22, 2024 | 60.64M |
| April 19, 2024 | 60.64M |
| April 18, 2024 | 60.64M |
| April 17, 2024 | 60.64M |
| April 16, 2024 | 60.64M |
| April 15, 2024 | 60.64M |
| April 12, 2024 | 60.64M |
| April 11, 2024 | 60.64M |
| April 10, 2024 | 60.64M |
| April 09, 2024 | 60.64M |
| April 08, 2024 | 65.12M |
| April 05, 2024 | 65.12M |
| April 04, 2024 | 65.12M |
| April 03, 2024 | 65.12M |
| April 02, 2024 | 65.12M |
| April 01, 2024 | 65.12M |
| March 28, 2024 | 65.12M |
| Date | Value |
|---|---|
| March 27, 2024 | 65.12M |
| March 26, 2024 | 65.12M |
| March 25, 2024 | 65.12M |
| March 22, 2024 | 65.12M |
| March 21, 2024 | 65.12M |
| March 20, 2024 | 65.12M |
| March 19, 2024 | 65.12M |
| March 18, 2024 | 65.12M |
| March 15, 2024 | 65.12M |
| March 14, 2024 | 65.12M |
| March 13, 2024 | 65.12M |
| March 12, 2024 | 65.12M |
| March 11, 2024 | 60.87M |
| March 08, 2024 | 60.87M |
| March 07, 2024 | 60.87M |
| March 06, 2024 | 60.87M |
| March 05, 2024 | 56.17M |
| March 04, 2024 | 56.17M |
| March 01, 2024 | 56.17M |
| February 29, 2024 | 56.17M |
| February 28, 2024 | 56.17M |
| February 27, 2024 | 56.17M |
| February 26, 2024 | 56.17M |
| February 23, 2024 | 57.96M |
| February 22, 2024 | 57.96M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
46.33M
Minimum
Nov 24 2023
10.83B
Maximum
Jun 20 2019
9.104B
Average
10.71B
Median
Aug 01 2022
Enterprise Value Benchmarks
| CEL-SCI Corp | 76.65M |
| AIM ImmunoTech Inc | 7.789M |
| IGC Pharma Inc | 31.90M |
| NovaBay Pharmaceuticals Inc | 2.666M |
| Protalix BioTherapeutics Inc | 60.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.8995M |
| Revenue (Quarterly) | 15.58M |
| Total Expenses (Quarterly) | 14.41M |
| EPS Diluted (Quarterly) | 1.01 |
| Gross Profit Margin (Quarterly) | 19.41% |
| Profit Margin (Quarterly) | 5.77% |